Document is current
Any future updates will be listed below
-
Authors
Mease, Philip https://orcid.org/0000-0002-6620-0457
Korotaeva, Tatiana https://orcid.org/0000-0003-0579-1131
Shesternya, Pavel https://orcid.org/0000-0001-8652-1410
Kokhan, Muza https://orcid.org/0000-0001-6353-6644
Rukavitsyn, Anton https://orcid.org/0000-0001-7598-5586
Vasilchenkov, Dmitry https://orcid.org/0000-0002-2809-3929
Sharaf, Mohamed https://orcid.org/0009-0003-9847-2996
Lavie, Frédéric https://orcid.org/0000-0002-5213-257X
Deodhar, Atul https://orcid.org/0000-0002-2130-1246
-
Funding
Funding for this research was provided by:
Janssen-Cilag Ltd
- License Information
-
More Information
Article History
Received: 5 June 2024
Accepted: 5 August 2024
First Online: 25 September 2024
Declarations
:
: Philip Mease: Research grants from AbbVie, Acelyrin, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, SUN, and UCB; consulting fees from AbbVie, Acelyrin, Aclaris, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Immagene, Janssen, Novartis, Pfizer, SUN, UCB, and Ventyx; and speaker fees from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. Tatiana Korotaeva: Consulting fees from Biocad, Janssen, Novartis, and Swixx; research grant funding from Pfizer; and speaker fees from AbbVie, Biocad, Janssen, and Novartis. Pavel Shesternya: Consulting and speaker fees from AbbVie, Biocad, Janssen, Novartis, Pfizer, and R-Pharm. Muza Kokhan: Consulting fees from Celgene, Johnson & Johnson, and Novartis; grant/research support from AbbVie, Celgene, Eli Lilly, Galderma, Johnson & Johnson, LEO Pharma, MSD, Novartis, Pfizer, and UCB; and speaker fees from AbbVie, Celgene, Eli Lilly, Galderma, Johnson & Johnson, Novartis, and UCB. Anton Rukavitsyn: Employee of Johnson & Johnson LLC, Russian Federation. Dmitry Vasilchenkov: Employee of Johnson & Johnson LLC, Russian Federation. Mohamed Sharaf: Employee of Johnson & Johnson EMEA, United Arab Emirates. Frédéric Lavie: Employee of Pharmaceutical Companies of Johnson & Johnson, France. Atul Deodhar: Consulting fees for participation in advisory boards from AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, MoonLake, Novartis, Pfizer, and UCB; research grant funding from AbbVie, Bristol Myers Squibb, Celgene, Eli Lilly, MoonLake, Novartis, Pfizer, and UCB; and speaker fees from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB.
: DISCOVER-1 and -2 were conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice. The study protocols were approved by ethics committees at each site. All participants provided written informed consent.
